

ADALIMUMAB

BRAND NAME	AMGEVITA, HADLIMA, HUMIRA, HYRIMOZ, IDACIO
DRUG CLASS	Antirheumatic, immunosuppressant, monoclonal antibody, TNF-alpha antagonist
AVAILABILITY	<p>Prefilled syringe, pen or auto-injector contains 20 mg/0.2 mL, 20 mg/0.4 mL, 40 mg/0.4 mL, or 40 mg/0.8 mL of adalimumab.¹</p> <p>Amgevita also contains sucrose, polysorbate-80, glacial acetic acid and sodium hydroxide.¹</p> <p>Hadlima also contains sodium citrate, citric acid, L-histidine, L-histidine hydrochloride, sorbitol and polysorbate-20.¹</p> <p>Humira 100 mg/mL presentations also contain mannitol and polysorbate-80.¹</p> <p>Humira 50 mg/mL presentations also contain sodium chloride, monobasic sodium phosphate, dibasic sodium phosphate, sodium citrate, citric acid, mannitol and polysorbate-80.¹</p> <p>Hyrimoz also contains sodium chloride, adipic acid, citric acid, mannitol, polysorbate-80, sodium chloride and hydrochloric acid.¹</p> <p>Idacio also contains monobasic sodium phosphate, dibasic sodium phosphate, mannitol, sodium chloride, citric acid, sodium citrate, polysorbate-80, and sodium hydroxide.¹</p> <p>Amgevita, Hadlima, Hyrimoz and Idacio are biosimilar products to Humira. The solution is clear and colourless.¹</p>
pH	5.2 ¹
PREPARATION	Ready to use
STABILITY	<p>Store at 2 to 8 °C. Do not freeze. Protect from light.¹</p> <p>After removal from the fridge:</p> <p>Amgevita, Humira and Idacio prefilled syringes and pens are stable for 14 days below 25 °C or at 2 to 8 °C. Protect from light.¹</p> <p>Hyrimoz prefilled syringe and pen are stable for 21 days below 25 °C or at 2 to 8 °C. Protect from light.¹</p> <p>Hadlima prefilled syringe and auto-injector are stable for 28 days below 25 °C or at 2 to 8 °C. Protect from light.¹</p>
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Inject into the abdomen or thigh. Rotate the site of injection. ¹ Do not shake. ² Suitable for self-administration after appropriate patient education. ¹
IV injection	Not recommended
IV infusion	Not recommended
COMPATIBILITY	Do not mix with other medicines
INCOMPATIBILITY	No information
SPECIAL NOTES	<p>May cause injection-site reactions including pain, swelling, redness, pruritus and haemorrhage.¹</p> <p>Hypersensitivity and anaphylaxis have been reported.¹</p>

REFERENCES

1. Product information. Available at www.tga.gov.au. Accessed 20/05/2022.
2. Consumer medicine information. Available at www.tga.gov.au. Accessed 19/07/2021.